WeVote
Log In

Bill

Bill

HB 233

TAX CREDITS: Establishes an income tax credit for certain pharmaceutical and medicine manufacturers (OR DECREASE GF RV See Note)

2025 Regular Session Introduced by Michael Echols

Louisiana bill creating an income tax credit for pharmaceutical manufacturers to incentivize business operations, with uncertain fiscal impact on state revenue.

Read by title, under the rules, referred to the Committee on Ways and Means.
0
WeVote Research Nonpartisan
Bill Summary · HB 233

Legislative bill overview

HB 233 establishes a state income tax credit for pharmaceutical and medicine manufacturers operating in Louisiana. The bill was prefiled in April 2025 and is currently under review by the Committee on Ways and Means. The exact parameters of the credit—including eligibility criteria, credit amount, and duration—are not detailed in the available information.

Why is this important

Tax credits for manufacturers directly affect state revenue and can influence business location decisions. This policy mechanism attempts to attract or retain pharmaceutical manufacturing operations in Louisiana, which could create jobs and economic activity. However, the fiscal impact depends entirely on the credit's design, which will determine how much general fund revenue the state foregoes.

Potential points of contention

  • Revenue cost unclear: The notation "OR DECREASE GF RV" suggests uncertainty about general fund impact, raising questions about fiscal accountability and whether the state can afford the credit
  • Targeted vs. broad incentives: Debate over whether tax credits should be industry-specific or available broadly; pharmaceutical credits may disadvantage other Louisiana industries seeking similar treatment
  • Effectiveness measurement: No apparent provisions mentioned for tracking job creation, investment returns, or other outcomes to justify the tax expenditure

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.